Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 4, 2010, Pages 541-548

  Farhat, Fadi S ^a,b   Kattan, Joseph ^c   Ghosn, Marwan G ^c  

^a Bellevue Medical Center   (Lebanon)

^b Hammoud Hospital   (Lebanon)

^c SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Advanced; Capecitabine; Combination; Gastric cancer; Irinotecan; Metastatic

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; GEFITINIB; IMATINIB; IRINOTECAN; OXALIPLATIN; TRASTUZUMAB;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; HYPOTENSION; LETHARGY; LEUKOPENIA; METASTASIS; NAUSEA; NEUTROPENIA; REVIEW; SINGLE DRUG DOSE; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG DESIGN; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77951213495     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.09.179     Document Type: Review

References (65)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC Cancerbase no. 5, version 2.0, IARC Press, Lyon, France (2004).
2. Parkin DM, Whelan SL, Ferlay J. Cancer Incidence in Five Continents Volume VII. International Agency for Research on Cancer, Lyon, France, 822-823 (1997).
3. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern. Med. 47(12), 1077-1083 (2008).
4. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 374(9688), 477-490 (2009).
5. Correa P, Chen VW. Gastric cancer. Cancer Surv. 19-20, 55-76 (1994). (Pubitemid 24289379)
6. Aragonés N, Pollán M, Rodero I, López-Abente G. Gastric cancer in the European Union (1968-1992): mortality trends and cohort effect. Ann. Epidemiol. 7(4), 294-303 (1997). (Pubitemid 27248653)
7. Stewart BW, Kleihues P. World Health Organization International Agency for Research on Cancer. World Cancer Report (2003).
8. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006). (Pubitemid 46655601)
9. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit. Rev. Oncol. Hematol. 71(2), 127-164 (2009). (Pubitemid 40703920)
10. Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol. 22, 2069-2077 (2004). (Pubitemid 41095139)
11. Ajani JA, Fodor MB, Tjulandin SA et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol. 23, 5660-5667 (2005). (Pubitemid 46300162)
12. Barone C, Corsi DC, Pozzo C et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin based regimen: two parallel randomized Phase II studies. Cancer 82, 1460-1467 (1998). (Pubitemid 28164990)
13. Bouche' O, Raoul JL, Bonnetain F et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J. Clin. Oncol. 22, 4319-4328 (2004). (Pubitemid 41199650)
14. Hong YS, Song SY, Lee SI et al. A Phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann. Oncol. 15, 1344-1347 (2004). (Pubitemid 39295021)
15. Kohne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a Phase II multicentric trial. Br. J. Cancer 89, 997-1001 (2003). (Pubitemid 37239201)
16. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T. A pilot Phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64, 232-236 (2003). (Pubitemid 36438808)
17. Moehler M, Eimermacher A, Siebler J et al. Randomised Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br. J. Cancer 92, 2122-2128 (2005). (Pubitemid 40973775)
18. Nardi M, Azzarello D, Maisano R et al. FOLFOX-4 regimen as firstline chemotherapy in elderly patients with advanced gastric cancer: a safety study. J. Chemother. 19, 85-89 (2007). (Pubitemid 46255477)
19. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J. Clin. Oncol. 24, 2188-2196 (2006). (Pubitemid 46630691)
20. Pozzo C, Barone C, Szanto J et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. 15, 1773-1781 (2004). (Pubitemid 40017161)
21. Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann. Surg. Oncol. 14(10), 2687-2690 (2007). (Pubitemid 47460625)
22. Koizumi W. Available options in chemotherapy for advanced gastric cancer: the current developments in Japan. Expert Opin. Pharmacother. 6(2), 225-231 (2005). (Pubitemid 40309125)
23. Van Cutsem E, Moiseyenko VM, Tjulandin S et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24(31), 4991-4997 (2006). (Pubitemid 46631401)
24. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J. Gastroenterol. 43(4), 256-264 (2008). (Pubitemid 351650035)
25. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352, 2696-2704 (2005). (Pubitemid 41007824)
26. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br. J. Cancer 90, 1190-1197 (2004). (Pubitemid 38496812)
27. Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a Phase II trial. Br. J. Cancer 92, 2129-2133 (2005). (Pubitemid 40966246)
28. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 34, 1274-1281 (1998). (Pubitemid 28342121)
29. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol. 45, 291-297 (2000). (Pubitemid 30151522)
30. Comella P, Franco L, Casaretti R, de Portu S, Menditto E. Emerging role of capecitabine in gastric cancer. Pharmacotherapy 29(3), 318-330 (2009).
31. Sakamoto J, Chin K, Kondo K et al.; Clinical Study Group of Capecitabine. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17(2), 231-236 (2006).
32. Lee JL, Kang YK, Kang HJ et al. A randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer 99(4), 584-590 (2008).
33. Cunningham D, Starling N, Rao S et al.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008).
34. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009).
35. Kim TW, Kang YK, Ahn JH et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol. 13, 1893-1898 (2002). (Pubitemid 36049952)
36. Kang HJ, Chang HM, Kim TW et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br. J. Cancer 92(2), 246-251 (2005). (Pubitemid 40347314)
37. Lee SS, Lee JL, Ryu MH et al. Combination chemotherapy with capecitabine (X) and cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn. J. Clin. Oncol. 37(1), 30-37 (2007). (Pubitemid 47096440)
38. Kang HJ, Chang HM, Kim TW et al. A Phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br. J. Cancer 98(2), 316-322 (2008). (Pubitemid 351161266)
39. Park YH, Ryoo BY, Choi SJ, Kim HT. A Phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer 90(7), 1329-1333 (2004). (Pubitemid 38586256)
40. Giordano KF, Jatoi A, Stella PJ et al.; North Central Cancer Treatment Group. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a Phase II study from the North Central Cancer Treatment Group. Ann. Oncol. 17(4), 652-656 (2006).
41. Orditura M, Martinelli E, Galizia G et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a Phase II study. Ann. Oncol. 17(10), 1529-1532 (2006). (Pubitemid 44542039)
42. Thuss-Patience PC, Kretzschmar A, Dogan Y et al. Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA, 30 May-3 June 2008.
43. Park YH, Kim BS, Ryoo BY, Yang SH. A Phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br. J. Cancer 94(7), 959-963 (2006).
44. van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a Phase II study. Br. J. Cancer 96(9), 1348-1352 (2007). (Pubitemid 46685802)
45. Jatoi A, Murphy BR, Foster NR et al; North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a Phase II study from the North Central Cancer Treatment Group. Ann. Oncol. 17(1), 29-34 (2006). (Pubitemid 43033836)
46. Kim TW, Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit. 29(3), 265-270 (2007). (Pubitemid 47262254)
47. Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med. Oncol. 24(2), 137-146 (2007). (Pubitemid 350139221)
48. Futatsuki K, Wakui A, Nakao I et al. Late Phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan. To. Kagaku. Ryoho. 21(7), 1033-1038 (1994). (Pubitemid 24225031)
49. Köhne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a Phase II multicentric trial. Br. J. Cancer 89(6), 997-1001 (2003). (Pubitemid 37239201)
50. Blanke CD, Haller DG, Benson AB et al. A Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann. Oncol. 12(11), 1575-1580 (2001).
51. Pozzo C, Barone C, Szanto J et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol. 15(12), 1773-1781 (2004). (Pubitemid 40017161)
52. Bouché O, Raoul JL, Bonnetain F et al; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J. Clin. Oncol. 22(21), 4319-4328 (2004). (Pubitemid 41199650)
53. Dank M, Zaluski J, Barone C et al. Randomized Phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol. 19(8), 1450-1457 (2008).
54. Baek JH, Kim JG, Jeon SB et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer 94(10), 1407-1411 (2006). (Pubitemid 43772274)
55. Burge ME, Smith D, Topham C et al. A Phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br. J. Cancer 94(9), 1281-1286 (2006).
56. Oh SC, Sur HY, Sung HJ et al. A Phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br. J. Cancer 96(10), 1514-1519 (2007). (Pubitemid 46762953)
57. Leary A, Assersohn L, Cunningham D et al. A Phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother. Pharmacol. 64(3), 455-462 (2009).
58. Farhat FS, Kattan J, Chahine GY et al. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer. Med. Oncol. (2009) (In press).
59. Moehler M, Kanzler S, Geissler M et al.; for the Arbeitsgemeinschaft Internistische Onkologie, Germany. A randomized multicenter Phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol. 21(1), 71-77 (2010).
60. Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 11(6), 602-611 (2006). (Pubitemid 43967615)
61. Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16(2), 273-278 (2005). (Pubitemid 40309309)
62. Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(Suppl. 20), 155 (2009) (Abstract LBA4509).
63. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. (2009) 71(1), 14-17 (2010).
64. Liakakos T, Roukos DH. More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. Ann. Surg. Oncol. 15, 956-960 (2008).
65. Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn. 9(3), 217-221 (2009).